1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,141 | 0,162 | 09:11 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT IND APPLICATION FOR SM17 ACCEPTED BY NMPA CDE | - | HKEx | ||
| 14.10.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT FIRST COHORT OF HEALTHY SUBJECTS DOSED WITH SUBCUTANEOUS FORMULATION OF SM17 IN A BRIDGING STUDY IN CHINA | - | HKEx | ||
| 08.10.25 | SINOMAB BIO-B (03681): CHANGE OF COMPANY SECRETARY | 1 | HKEx | ||
| 26.09.25 | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 26.09.25 | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 26.09.25 | SINOMAB BIO-B (03681): INTERIM REPORT 2025 | - | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 29.08.25 | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 29.08.25 | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.08.25 | SINOMAB BIO-B (03681): COMPLETION OF SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 18.08.25 | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.08.25 | SINOMAB BIO-B (03681): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 15.08.25 | SINOMAB BIO-B (03681): COMPLETION OF CERTAIN SUBSCRIPTIONS OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 12.08.25 | SINOMAB BIO-B (03681): VOLUNTARY ANNOUNCEMENT COMPREHENSIVE STRATEGIC COOPERATION AGREEMENT | 1 | HKEx | ||
| 09.04.25 | SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis | 495 | JCN Newswire | - Potentially a First-and Best-in-Class Product- Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 309,11 | 0,00 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| COGENT BIOSCIENCES | 37,960 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,650 | -0,27 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,060 | -2,77 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ARCELLX | 69,47 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,570 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,62 | +4,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,93 | +2,15 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| QIAGEN | 44,060 | 0,00 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| ERASCA | 10,610 | 0,00 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 4,175 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,300 | +3,03 % | New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug | ||
| ALUMIS | 26,420 | +7,79 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen SINOMAB BIOSCIENCE LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,198 Euro und damit +32,89 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SINOMAB BIOSCIENCE LTD finden Sie auf Wallstreet Online.